SPOTLIGHT: Shareholders blast Dendreon


Angry shareholders have sued Dendreon, claiming that the company misrepresented its clinical data for Provenge and failed to provide clear guidance on when the FDA would make its decision on the prostate cancer drug. Several weeks ago the agency demanded more data on Provenge before it could be approved. Report